391 related articles for article (PubMed ID: 21765020)
41. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
Castillo JJ; Gertz MA
Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
[TBL] [Abstract][Full Text] [Related]
42. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
Yokota S; Urasaki Y; Nakamura Y; Bessho M
Rinsho Ketsueki; 2012 Mar; 53(3):303-9. PubMed ID: 22499046
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
44. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
45. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.
Rögnvaldsson S; Love TJ; Thorsteinsdottir S; Reed ER; Óskarsson JÞ; Pétursdóttir Í; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Eyþórsson E; Jónsson Á; Björnsson AS; Gunnarsson GÞ; Pálsson R; Indriðason ÓS; Gíslason GK; Ólafsson A; Hákonardóttir GK; Brinkhuis M; Halldórsdóttir SL; Ásgeirsdóttir TL; Steingrímsdóttir H; Danielsen R; Dröfn Wessman I; Kampanis P; Hultcrantz M; Durie BGM; Harding S; Landgren O; Kristinsson SY
Blood Cancer J; 2021 May; 11(5):94. PubMed ID: 34001889
[TBL] [Abstract][Full Text] [Related]
46. Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study.
Kuwabara C; Sakuma Y; Kume A; Tamura Y; Shimizu R; Iwai R; Ishii A; Tanaka H
Int J Hematol; 2019 Feb; 109(2):154-161. PubMed ID: 30406907
[TBL] [Abstract][Full Text] [Related]
47. Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance.
Castañeda-Avila MA; Lapane KL; Person SD; Jesdale BM; Zhou Y; Mazor KM; Epstein MM
Cancer Control; 2022; 29():10732748221126936. PubMed ID: 36112886
[TBL] [Abstract][Full Text] [Related]
48. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
49. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Greenberg AJ; Rajkumar SV; Vachon CM
Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
[TBL] [Abstract][Full Text] [Related]
50. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
51. Active multiple myeloma suppresses and typically eliminates coexisting MGUS.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Br J Cancer; 2017 Sep; 117(6):835-839. PubMed ID: 28728165
[TBL] [Abstract][Full Text] [Related]
52. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS).
Castañeda-Avila MA; Mazor KM; Lapane KL; Epstein MM
Cancer Causes Control; 2023 May; 34(5):449-457. PubMed ID: 36853428
[TBL] [Abstract][Full Text] [Related]
53. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
54. Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.
Landgren O; Shim YK; Michalek J; Costello R; Burton D; Ketchum N; Calvo KR; Caporaso N; Raveche E; Middleton D; Marti G; Vogt RF
JAMA Oncol; 2015 Nov; 1(8):1061-8. PubMed ID: 26335650
[TBL] [Abstract][Full Text] [Related]
55. Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.
Clay-Gilmour AI; Kumar S; Rajkumar SV; Rishi A; Kyle RA; Katzmann JA; Murray DL; Norman AD; Greenberg AJ; Larson DR; O'Byrne MM; Slager SL; Vachon CM
Leukemia; 2019 Feb; 33(2):499-507. PubMed ID: 30201985
[TBL] [Abstract][Full Text] [Related]
56. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Goyal G; Rajkumar SV; Lacy MQ; Gertz MA; Buadi FK; Dispenzieri A; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kourelis TV; Warsame R; Kyle RA; Kumar SK
Leukemia; 2019 May; 33(5):1273-1277. PubMed ID: 30787429
[TBL] [Abstract][Full Text] [Related]
57. Follow-up monoclonal gammopathy of undetermined significance in kidney transplant.
Cuéllar-García C; Sevillano Ruiz-Mateos C; Mazuecos Blanca MA; Narvaez Mejia C; Fernandez Valle MC; Martin Reina V; Gonzalez Bernal M; Yera Cobo M; Rodriguez Lopez R; de Cos Hohr C; Garrastazul MP; Marchante I; Paz Coll A; Capote Huelva FJ
Transplant Proc; 2015; 47(1):78-80. PubMed ID: 25645776
[TBL] [Abstract][Full Text] [Related]
58. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
59. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Lindqvist EK; Landgren O; Lund SH; Turesson I; Hultcrantz M; Goldin L; Björkholm M; Kristinsson SY
Ann Hematol; 2017 Feb; 96(2):261-269. PubMed ID: 27807648
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes.
Garderet L; Al Hariri M; Wasielica-Poslednik J; Munder M; Kormányos K; Pena C; Gozzetti A; Zhou X; Waszczuk-Gajda A; Rosinol L; Mikala G; Krzystanski M; Lisch W; Vesole D; Szentmáry N; Jurczyszyn A
Leuk Lymphoma; 2022 Apr; 63(4):984-990. PubMed ID: 34823428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
